Research graph
References from Treatment-resistant Parkinson's disease psychosis responding to xanomeline-trospium: A case report. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
2024 · External reference
Epidemiology of psychosis in Parkinson’s disease
10.1016/j.jns.2009.08.014 · 2010 · External reference
The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease
2011 · External reference
Parkinson disease psychosis: update
10.1155/2013/645429 · 2013 · External reference
International Parkinson and Movement Disorder Society evidence-based medicine review
10.1002/mds.27372 · 2018 · External reference
Clozapine in drug-induced psychosis in Parkinson’s disease
10.1056/nejm199903113401003 · 1999 · External reference
Pimavanserin for patients with Parkinson’s disease psychosis
10.1016/s0140-6736(13)62106-6 · 2014 · External reference
Assessment of pimavanserin safety and efficacy in Parkinson disease psychosis
2023 · External reference
Successful use of high-dose brexpiprazole for psychosis in Lewy body dementia without adverse effects
10.5152/pcp.2024.23772 · 2024 · External reference
Effects of xanomeline in Alzheimer disease
10.1001/archneur.1997.00550160091022 · 1997 · External reference
Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia
10.1176/appi.ajp.2008.06091591 · 2008 · External reference
Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia
2023 · External reference
EMERGENT-2 trial
10.1016/s0140-6736(23)02190-6 · 2024 · External reference
Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial
10.1001/jamapsychiatry.2024.0785 · 2024 · External reference
Allosteric modulation of M4 muscarinic receptors as a treatment strategy for psychosis
2017 · External reference
